inflammation – Medxy AI

Interleukin-6 as a Central Mediator of Therapeutic Success in Acute Lung Injury and COVID-19

By MedXY 08/06/2026

This article examines interleukin-6 (IL-6) as a key mediator of therapeutic efficacy in acute lung injury and COVID-19, highlighting its role in modulating inflammation and survival outcomes across multiple clinical interventions.

Clinical Updates Neurology news

Serum Ferritin and Inflammation in Isolated REM Sleep Behavior Disorder: Insights from Longitudinal Cohort Studies

By MedXY 08/06/2026

This review explores the role of dysregulated iron metabolism and inflammation, particularly elevated serum ferritin, in isolated REM sleep behavior disorder (iRBD) as a prodromal stage of neurodegeneration, synthesizing recent longitudinal evidence and its clinical implications.

Critical Care news

Burn Injury Reprograms Extracellular Vesicle Communication: Linking Immune Activation and Neuroinflammation

By MedXY 08/02/2026

Severe burns alter extracellular vesicle protein cargo, revealing coordinated immune and neuronal signaling changes that drive inflammation and healing responses, suggesting novel biomarker and therapeutic avenues.

Cardiology Diabetes & Endocrinology news

GLP-1 Receptor Agonists: A Breakthrough in Reducing Atherosclerosis and Cardiovascular Risk Beyond Diabetes and Obesity

By MedXY 07/22/2026

GLP-1 receptor agonists significantly reduce atherosclerosis progression, inflammatory biomarkers, and cardiovascular events independent of glycaemic control and obesity status, evidenced by robust preclinical and large-scale clinical data.

Cardiology news

Inflammation as a Modifier of Lipoprotein(a)–Associated Cardiovascular Risk: Insights from the UK Biobank

By MedXY 06/27/2026

Elevated lipoprotein(a) increases coronary artery disease risk, but this study reveals that inflammation—particularly IL-6 levels—modulates this risk, highlighting the importance of inflammatory biomarkers in cardiovascular risk assessment and prevention strategies.

Cardiology news Public Health

The Prognostic Value of Serum Interleukin-6 Concentrations for 9 Cardiovascular and Mortality Outcomes

By MedXY 06/10/2026

Higher blood IL-6 levels were strongly linked to nine cardiovascular and mortality outcomes in nearly 60,000 adults, supporting IL-6 as an important inflammatory marker and potential prevention target.

news Psychiatry Public Health

Interleukin 6 as a Treatment Target for Depression: A Proof-of-Concept Randomized Clinical Trial

By MedXY 06/03/2026

A small randomized trial found that blocking IL-6 with tocilizumab showed promising, clinically meaningful trends for inflammation-related, hard-to-treat depression, especially for somatic symptoms, fatigue, anxiety, and quality of life, though results were not statistically significant.

Cardiology Internal Medicine news

Higher Interleukin-6 Levels Predict Broad Cardiovascular Risk and Mortality Across Diverse Cohorts

By MedXY 05/31/2026

A pooled analysis of 59,396 participants found that higher serum IL-6 concentrations independently predicted nine cardiovascular and mortality outcomes, with consistent associations across key clinical subgroups.

Cardiology Diabetes & Endocrinology news

Chronic Inflammation via suPAR: The Missing Link Between Diabetes and Cardiovascular Mortality

By MedXY 03/15/2026

A landmark study in Diabetes Care reveals that soluble urokinase plasminogen activator receptor (suPAR) mediates over half of the increased risk for adverse cardiovascular outcomes in patients with diabetes and coronary artery disease, surpassing traditional inflammatory markers like hs-CRP.

Cardiology news

PRMT9 and Heart Recovery: A New Frontier in Macrophage Modulation and STAT1 Degradation

By MedXY 03/02/2026

Researchers have discovered that the protein PRMT9 plays a vital role in healing the heart after a myocardial infarction by controlling inflammatory macrophages. By promoting the degradation of the STAT1 protein, PRMT9 reduces tissue damage and improves cardiac function.

news Psychiatry Public Health

Unpacking the ‘Weathering’ Hypothesis: How Cumulative Lifespan Stress and Inflammation Drive Racial Disparities in Mortality

By MedXY 02/10/2026

A longitudinal study identifies that cumulative lifetime stress and systemic inflammation mediate nearly 50% of the mortality gap between Black and White adults, providing a biological link between structural inequity and premature death.

Family Medicine & Nutrition Internal Medicine news Rheumatology

The Tart Cherry Revolution: A Deep Dive into the Science of Longevity, Recovery, and Restorative Sleep

By MedXY 02/07/2026

This article explores the multi-faceted health benefits of tart cherry juice, from its potent anti-inflammatory properties to its role in enhancing sleep and cardiovascular health, supported by the latest clinical research.

Neurology news Radiology

Atorvastatin Attenuates Aneurysmal Wall Inflammation in Vertebrobasilar Dissecting Aneurysms: Insights from a Randomized Controlled Trial

By MedXY 01/21/2026

A randomized controlled trial demonstrates that 6-month atorvastatin treatment significantly reduces aneurysm wall enhancement and systemic inflammatory markers in patients with unruptured vertebrobasilar dissecting aneurysms, potentially offering a non-invasive stabilizing therapy for these high-risk lesions.

Cardiology Internal Medicine news

Beyond Standard Risk Factors: High-Sensitivity C-Reactive Protein as a Critical Driver of Cardiovascular Risk Prediction

By MedXY 01/05/2026

Recent large-scale studies demonstrate that high-sensitivity C-reactive protein (hsCRP) is a potent, stable predictor of cardiovascular events, even in individuals without traditional risk factors. Despite its clinical utility in improving risk reclassification, barriers to widespread adoption in clinical practice remain.

Infectious Diseases Internal Medicine news

Colchicine for Long COVID: Randomized Trial Finds No Benefit in Functional Recovery or Inflammatory Resolution

By MedXY 01/01/2026

A multi-center randomized clinical trial published in JAMA Internal Medicine demonstrates that colchicine, despite its potent anti-inflammatory properties, fails to improve 6-minute walk test distances or inflammatory markers in patients suffering from Long COVID, highlighting the complexity of the condition's pathogenesis.

Diabetes & Endocrinology news

Dietary Inflammatory and Insulinemic Potentials Drive Type 2 Diabetes Progression Following Gestational Diabetes: Insights from the Nurses’ Health Study II

By MedXY 12/30/2025

A prospective study of 4,318 women reveals that dietary patterns promoting inflammation and hyperinsulinemia significantly elevate the risk of progressing from gestational diabetes to type 2 diabetes, with BMI serving as a primary mediator of this metabolic transition.

Critical Care news Respiratory

Inflammatory Subphenotypes in COVID-19 ARDS Exhibit High Temporal Stability: Insights from the ICAR Trial

By MedXY 12/27/2025

A reanalysis of the ICAR trial reveals that ARDS inflammatory subphenotypes remain remarkably stable over 28 days. The hyperinflammatory profile is linked to higher mortality and distinct biomarkers, with Bayesian modeling showing minimal transitions between phenotypes over time.

Cardiology Internal Medicine news

Calprotectin: A Mechanistically Informed Biomarker for Predicting Atherosclerotic Cardiovascular Disease

By MedXY 12/24/2025

A longitudinal study from the Dallas Heart Study identifies calprotectin as a significant, independent predictor of ASCVD events, linking neutrophil activation to endothelial dysfunction and increased cardiovascular risk across diverse populations.

news Psychiatry Radiology

Mapping the Neuro-Immune Divide: Distinct Brain-Blood Signatures Distinguish Early Depression from Psychosis

By MedXY 12/24/2025

A large-scale multicenter study identifies unique multivariate patterns of peripheral inflammation and brain structure that differentiate early-stage depression and psychosis, highlighting the influence of childhood trauma and cognitive performance on these distinct neurobiological signatures.

Cardiology Clinical Updates news

Cellular Adhesion Molecules as Prognostic Biomarkers and Therapeutic Insights in Chronic Heart Failure: Integrative Review Emphasizing DAPA-HF Findings

By MedXY 12/03/2025

Elevated VCAM-1 levels correlate with worse outcomes in chronic HFrEF, independent of conventional markers; dapagliflozin’s benefits are consistent across VCAM-1 levels, highlighting inflammatory pathways as therapeutic targets.